Al Sakka Amini Ruaa, Ismail Abdel-Latif S, Al-Aqrabawi Maysarah, Aleyadeh Wesam, Mohammed Abdul, Altork Nadera, Abosheaishaa Hazem, Elfert Khaled A, Goble Spencer R, Sawaf Bisher, Chandan Saurabh
Nephrology, Abdali Hospital, Amman, JOR.
Internal Medicine, University of Maryland Medical Center, Baltimore, USA.
Cureus. 2024 Aug 6;16(8):e66311. doi: 10.7759/cureus.66311. eCollection 2024 Aug.
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are gaining popularity in the management of diabetes mellitus and obesity. It has been suggested that this class of medications causes delayed gastric emptying which raised concerns about the potential for aspiration of gastric contents in patients undergoing sedation. This led to a statement by the American Society of Anesthesiologists about their preoperative use. Nevertheless, there is minimal evidence regarding the effects of GLP-1RAs on the risk of aspiration post-esophagogastroduodenoscopy (EGD). In this study, we sought to evaluate the incidence of aspiration and pneumonia in patients receiving GLP-1RAs who underwent EGD. Methodology We performed a retrospective cohort study in TriNetX, a global federated research network of electronic health records. The primary outcome was the development of aspiration post-EGD. Secondary outcomes were the development of aspiration pneumonia and requiring antibiotics post-EGD. One-to-one propensity score matching was performed for age, sex, diabetes mellitus, obesity, and other comorbidities between the cohorts. Results Our analysis showed a small but significant risk of aspiration pneumonitis in patients on GLP-1RAs undergoing elective EGD compared to non-GLP-1RA-receiving patients. However, there was no increased risk of the composite outcome of respiratory failure or intensive care unit (ICU) admission; however, this did not reach statistical significance. Conclusions GLP-1RA use was associated with an increased risk of aspiration in patients undergoing elective upper endoscopy. However, this did not translate to an increased risk of respiratory failure or ICU admission. Our findings highlight the importance of following an individualized approach to preoperative management that takes into consideration GLP-1RA indications and other aspiration risk factors, including advanced age, impaired gag reflex, and gastrointestinal symptoms such as nausea and abdominal distention.
背景 胰高血糖素样肽-1受体激动剂(GLP-1RAs)在糖尿病和肥胖症的管理中越来越受欢迎。有人提出,这类药物会导致胃排空延迟,这引发了人们对接受镇静的患者发生胃内容物误吸可能性的担忧。这导致美国麻醉医师协会发表了关于其术前使用的声明。然而,关于GLP-1RAs对食管胃十二指肠镜检查(EGD)后误吸风险影响的证据极少。在本研究中,我们试图评估接受GLP-1RAs并接受EGD的患者中误吸和肺炎的发生率。
方法 我们在TriNetX(一个全球电子健康记录联合研究网络)中进行了一项回顾性队列研究。主要结局是EGD后发生误吸。次要结局是EGD后发生误吸性肺炎以及需要使用抗生素。对队列之间的年龄、性别、糖尿病、肥胖症和其他合并症进行一对一倾向评分匹配。
结果 我们的分析表明,与未接受GLP-1RA的患者相比,接受择期EGD的GLP-1RA患者发生误吸性肺炎的风险虽小但具有统计学意义。然而,呼吸衰竭或重症监护病房(ICU)入院这一复合结局的风险并未增加;不过,这未达到统计学意义。
结论 使用GLP-1RA与择期上消化道内镜检查患者误吸风险增加有关。然而,这并未转化为呼吸衰竭或ICU入院风险的增加。我们的研究结果强调了采用个体化术前管理方法的重要性,该方法应考虑GLP-1RA的适应证以及其他误吸风险因素,包括高龄、咽反射受损以及恶心和腹胀等胃肠道症状。